Sat 8/24/2019 18:52 ET
DJIA25628.90607.402.37%TELCO175.882.781.58%GOLD1536.7528.281.84%Shanghai2897.1413.910.48%
S&P 5002847.1173.742.59%BANKS411.4111.352.76%OIL53.951.402.59%BITCOIN10367.2643.540.42%
NASDAQ7751.77232.553.00%PHARM540.8912.602.33%US/EU1.110.000.01%Futures2851.2571.002.49%
Welcome Stranger!  Please sign up or log in to enable additional features.Sign Up | Mail | Log In
Forum - Nabriva Therapeutics AG - NBRV   

Return Top | Return List | Reply Thread | Search | Add NBRV | Ignore NBRV
From: burp (Rep: 73)Date: 2018-12-20 07:38:37
Forum: Nabriva Therapeutics AG - Thread #674053008Msg #97 - Part 1/2 (Rec: 0)
Both formulations of lefamulin were granted Qualified Infectious Disease Product and Fast Track designation by the FDA, enabling potential Priority Review of the NDAs by the FDA. Nabriva Therapeutics plans to submit a marketing authorization application for lefamulin in Europe in the first quarter of 2019.
Message: Endorse | Reply | Privately | Bookmark | Report Abuse User burp: Reward | Watch | Ignore

From: 1stockwilly (Rep: 105) reply to burpDate: 2018-12-20 14:53:53
Forum: Nabriva Therapeutics AG - Thread #674053008Msg #98 - Part 2/2 (Rec: 0)
Re: Both formulations of lefamulin were granted Qualified Infectious Disease Prod...

Give it a kick in the rear so it takes off.
Message: Endorse | Reply | Privately | Bookmark | Report Abuse User 1stockwilly: Reward | Watch | Ignore


TheLion.com | About Us | Agreement & Disclaimer | Privacy | Twitter
© 1999- TheLion.com, Inc.